MLTX vs. CD
MLTX (MoonLake Immunotherapeutics) and CD (Chaince Digital Holdings Inc) are both stocks. MLTX operates in Biotechnology (Healthcare), while CD operates in Capital Markets (Financial Services). Over the past 5 years, MLTX returned 12.70%/yr vs 2.32%/yr for CD. At a 0.05 correlation, their price movements are largely independent.
Performance
MLTX vs. CD - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MLTX achieves a 38.62% return, which is significantly lower than CD's 60.97% return.
MLTX
- 1D
- 2.24%
- 1M
- 4.04%
- YTD
- 38.62%
- 6M
- 36.85%
- 1Y
- -62.37%
- 3Y*
- -13.16%
- 5Y*
- 12.70%
- 10Y*
- —
CD
- 1D
- -11.41%
- 1M
- 48.98%
- YTD
- 60.97%
- 6M
- 13.64%
- 1Y
- 125.35%
- 3Y*
- 50.01%
- 5Y*
- 2.32%
- 10Y*
- -21.69%
MLTX vs. CD - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
MLTX MoonLake Immunotherapeutics | 38.62% | -75.66% | -10.33% | 475.14% | 6.17% | -13.02% | 8.39% |
CD Chaince Digital Holdings Inc | 60.97% | -27.23% | 162.69% | 109.41% | -64.75% | 3.93% | 10.11% |
Correlation
The correlation between MLTX and CD is -0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.00 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.07 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.06 |
Correlation (All Time) Calculated using the full available price history since Oct 21, 2020 | 0.05 |
Fundamentals
MLTX:
-$3.90
CD:
-$0.23
MLTX:
$0.00
CD:
$1.67M
MLTX:
-$1.49M
CD:
-$1.10M
MLTX:
-$179.84M
CD:
-$10.65M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MLTX vs. CD — Risk / Return Rank
MLTX
CD
MLTX vs. CD - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and Chaince Digital Holdings Inc (CD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| MLTX | CD | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.22 | ||
| Sortino ratioReturn per unit of downside risk | -1.49 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 1.29 | -0.12 |
| Calmar ratioReturn relative to maximum drawdown | -0.70 | 1.40 | -2.10 |
| Martin ratioReturn relative to average drawdown | -0.99 | 1.91 | -2.91 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| MLTX | CD | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.54 | 0.68 | -1.22 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.14 | 0.02 | +0.13 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | -0.15 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.12 | -0.18 | +0.31 |
Drawdowns
MLTX vs. CD - Drawdown Comparison
The maximum MLTX drawdown since its inception was -90.22%, smaller than the maximum CD drawdown of -99.79%. Use the drawdown chart below to compare losses from any high point for MLTX and CD.
Loading charts...
Drawdown Indicators
| MLTX | CD | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.22% | -99.79% | +9.57% |
Max Drawdown (1Y)Largest decline over 1 year | -89.93% | -89.83% | -0.10% |
Max Drawdown (3Y)Largest decline over 3 years | -90.22% | -89.83% | -0.39% |
Max Drawdown (5Y)Largest decline over 5 years | -90.22% | -93.02% | +2.80% |
Max Drawdown (10Y)Largest decline over 10 years | — | -99.58% | — |
Current DrawdownCurrent decline from peak | -71.39% | -97.00% | +25.61% |
Average DrawdownAverage peak-to-trough decline | -29.15% | -89.96% | +60.81% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 62.80% | 65.74% | -2.94% |
Volatility
MLTX vs. CD - Volatility Comparison
The current volatility for MoonLake Immunotherapeutics (MLTX) is 18.88%, while Chaince Digital Holdings Inc (CD) has a volatility of 49.09%. This indicates that MLTX experiences smaller price fluctuations and is considered to be less risky than CD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MLTX | CD | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.88% | 49.09% | -30.21% |
Volatility (6M)Calculated over the trailing 6-month period | 56.83% | 107.71% | -50.88% |
Volatility (1Y)Calculated over the trailing 1-year period | 117.11% | 185.49% | -68.38% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 91.12% | 151.47% | -60.35% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 86.52% | 145.86% | -59.34% |
Dividends
MLTX vs. CD - Dividend Comparison
Neither MLTX nor CD has paid dividends to shareholders.
Financials
MLTX vs. CD - Financials Comparison
This section allows you to compare key financial metrics between MoonLake Immunotherapeutics and Chaince Digital Holdings Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MLTX and CD have a correlation of -0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CD has higher volatility (49.09%) compared to MLTX (18.88%). In terms of maximum drawdown, MLTX dropped -90.22% vs CD's -99.79%.
CD currently has the higher Sharpe Ratio (0.68 vs -0.54), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MLTX and CD
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer